CN109963834B - 可用作皮质儿茶酚胺能神经传递调节剂的新型氮杂环丁烷衍生物 - Google Patents

可用作皮质儿茶酚胺能神经传递调节剂的新型氮杂环丁烷衍生物 Download PDF

Info

Publication number
CN109963834B
CN109963834B CN201780069687.6A CN201780069687A CN109963834B CN 109963834 B CN109963834 B CN 109963834B CN 201780069687 A CN201780069687 A CN 201780069687A CN 109963834 B CN109963834 B CN 109963834B
Authority
CN
China
Prior art keywords
azetidine
difluorophenoxy
trifluorophenoxy
compound
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780069687.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN109963834A (zh
Inventor
C·索内松
F·彼得松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NTG Nordic Transport Group AS
Original Assignee
Neurosearch AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch AS filed Critical Neurosearch AS
Publication of CN109963834A publication Critical patent/CN109963834A/zh
Application granted granted Critical
Publication of CN109963834B publication Critical patent/CN109963834B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201780069687.6A 2016-11-18 2017-11-17 可用作皮质儿茶酚胺能神经传递调节剂的新型氮杂环丁烷衍生物 Active CN109963834B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16199545 2016-11-18
EP16199545.1 2016-11-18
PCT/EP2017/079666 WO2018091687A1 (en) 2016-11-18 2017-11-17 Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission

Publications (2)

Publication Number Publication Date
CN109963834A CN109963834A (zh) 2019-07-02
CN109963834B true CN109963834B (zh) 2023-04-14

Family

ID=57348567

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780069687.6A Active CN109963834B (zh) 2016-11-18 2017-11-17 可用作皮质儿茶酚胺能神经传递调节剂的新型氮杂环丁烷衍生物

Country Status (10)

Country Link
US (1) US10875829B1 (enExample)
EP (1) EP3541784B1 (enExample)
JP (1) JP6990702B2 (enExample)
CN (1) CN109963834B (enExample)
DK (1) DK3541784T5 (enExample)
ES (1) ES2962865T3 (enExample)
FI (1) FI3541784T3 (enExample)
PL (1) PL3541784T3 (enExample)
PT (1) PT3541784T (enExample)
WO (1) WO2018091687A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112198237B (zh) * 2020-05-28 2021-08-06 扬子江药业集团广州海瑞药业有限公司 一种盐酸奈康唑杂质检测控制分析方法
WO2025008504A1 (en) 2023-07-06 2025-01-09 Integrative Research Laboratories Sweden Ab Pharmaceutically acceptable salts of 3-(2,3-difluorophenoxy)azetidine and uses thereof
WO2025008506A1 (en) 2023-07-06 2025-01-09 Integrative Research Laboratories Sweden Ab 3-(2,3-difluorophenoxy)azetidine, or a pharmaceutically acceptable salt thereof, for use in the treatment and/or prevention of pathological apathy

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004113297A2 (en) * 2003-06-24 2004-12-29 Neurosearch A/S Aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
WO2010022055A2 (en) * 2008-08-20 2010-02-25 Amgen Inc. Inhibitors of voltage-gated sodium channels
WO2011103196A1 (en) * 2010-02-17 2011-08-25 Amgen Inc. Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
CN102224135A (zh) * 2008-11-24 2011-10-19 Nsab神经研究瑞典公司分公司 用作皮质儿茶酚胺能神经传递调节剂的新3-苯基-氮杂环丁烷衍生物
WO2016030310A1 (en) * 2014-08-27 2016-03-03 F. Hoffmann-La Roche Ag Substituted azetidine derivatives as taar ligands
WO2016073420A1 (en) * 2014-11-05 2016-05-12 Dart Neuroscience, Llc Substituted azetidinyl compounds as glyt1 inhibitors
AU2016263510A1 (en) * 2015-05-20 2017-12-07 Integrative Research Laboratories Sweden Ab Novel azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
WO2007148185A2 (en) 2006-06-21 2007-12-27 Pfizer Products Inc. Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
ES2402713T3 (es) 2008-11-24 2013-05-08 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Derivados de 3-fenilo-3-metoxipirrolidina como moduladores de la transmisión catecolaminérgica cortical
JP2012515760A (ja) 2009-01-20 2012-07-12 ファイザー・インク 置換ピラジノンアミド
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
JP2014516074A (ja) 2011-06-07 2014-07-07 ファイザー・インク ピラゾロ［３，４−ｄ］ピリミジン化合物ならびにそのＰＤＥ２阻害剤および／またはＣＹＰ３Ａ４阻害剤としての使用
KR101273566B1 (ko) 2011-09-05 2013-06-11 한국과학기술연구원 신규한 아제티딘 유도체 및 이를 함유하는 항우울제 조성물
HK1199879A1 (en) * 2012-01-26 2015-07-24 H.隆德贝克有限公司 Pde9 inhibitors with imidazo triazinone backbone
CN108026030B (zh) 2015-09-18 2020-10-09 正大天晴药业集团股份有限公司 一种氘代化合物的制备方法
JOP20190077A1 (ar) * 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004113297A2 (en) * 2003-06-24 2004-12-29 Neurosearch A/S Aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
WO2010022055A2 (en) * 2008-08-20 2010-02-25 Amgen Inc. Inhibitors of voltage-gated sodium channels
CN102224135A (zh) * 2008-11-24 2011-10-19 Nsab神经研究瑞典公司分公司 用作皮质儿茶酚胺能神经传递调节剂的新3-苯基-氮杂环丁烷衍生物
WO2011103196A1 (en) * 2010-02-17 2011-08-25 Amgen Inc. Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
WO2016030310A1 (en) * 2014-08-27 2016-03-03 F. Hoffmann-La Roche Ag Substituted azetidine derivatives as taar ligands
WO2016073420A1 (en) * 2014-11-05 2016-05-12 Dart Neuroscience, Llc Substituted azetidinyl compounds as glyt1 inhibitors
AU2016263510A1 (en) * 2015-05-20 2017-12-07 Integrative Research Laboratories Sweden Ab Novel azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission

Also Published As

Publication number Publication date
DK3541784T5 (da) 2024-09-16
WO2018091687A1 (en) 2018-05-24
US10875829B1 (en) 2020-12-29
JP2019535715A (ja) 2019-12-12
PL3541784T3 (pl) 2024-03-11
FI3541784T3 (fi) 2023-10-02
EP3541784A1 (en) 2019-09-25
JP6990702B2 (ja) 2022-01-13
DK3541784T3 (en) 2023-10-23
CN109963834A (zh) 2019-07-02
EP3541784B1 (en) 2023-09-13
ES2962865T3 (es) 2024-03-21
PT3541784T (pt) 2023-11-22

Similar Documents

Publication Publication Date Title
US8633318B2 (en) Compounds for treatment or prevention of inflammation, an inflammatory disease, or an immune or an autoimmune disorder
JP2007501272A (ja) 置換イミダゾロピラジンおよびトリアゾロピラジン誘導体類：ｇａｂａａレセプタリガンド類
CN109963834B (zh) 可用作皮质儿茶酚胺能神经传递调节剂的新型氮杂环丁烷衍生物
RS58546B1 (sr) Deuterizovani 1-piperazino-3-fenil indani za tretiranje šizofrenije
KR101660936B1 (ko) 피질 카테콜아민성 신경전달의 조절자로서의 ３-페닐-３-메톡시피롤리딘 유도체
US20250042905A1 (en) Dihydropyrrolo[3,4-c]pyrazole derivatives and their use in diagnosis
Bernard-Gauthier et al. Development of subnanomolar radiofluorinated (2-pyrrolidin-1-yl) imidazo [1, 2-b] pyridazine pan-Trk inhibitors as candidate PET imaging probes
US10287247B2 (en) Azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission
JP2023507180A (ja) Ｏｇａ阻害剤化合物
JP6055784B2 (ja) パロキセチン誘導体
HK1245251A1 (en) Novel azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission
US20250100981A1 (en) Cis-substituted 5-(hydroxymethyl)morpholine-2-carboxamides as agonists of SSTR4
HK1147260A (en) Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant